Research progress of TNKS as drug target
10.3969/j.issn.1001-1978.2018.09.006
- VernacularTitle:端锚聚合酶作为药物靶点的研究进展
- Author:
Gen LI
1
;
Dong ZHAO
;
Jian LI
;
Xiu-Shan YIN
;
Wan-Zhong ZHANG
Author Information
1. 沈阳化工大学制药与生物工程学院
- Keywords:
TNKS;
PARP family;
regulation of cell function;
poly(ADP-ribosylation);
drug target;
inhibitor
- From:
Chinese Pharmacological Bulletin
2018;34(9):1206-1210
- CountryChina
- Language:Chinese
-
Abstract:
TNKSs are members of poly ( ADPribose) polymera-ses, which are different from other members of the PARP family with two unique structures: SAM domain and ankyrin repeat re-gion. TNKS participates in a variety of cellular function regula-tion, including telomere’ s dynamic balance, Wnt signaling pathways, glucose metabolism and spindle formation during mi-tosis. TNKS, as a very attractive drug target, regulates the sta-bility of target proteins via poly ( ADP-ribosylation). In recent years, the significant progress has been made for PARP inhibi-tors in cancer treatment. Multiple PARP inhibitors have entered different clinical evaluation stages. AstraZeneca's Olaparib, Clo-vis's Rucaparib, Merck's Niraparib come into existence in the market. This paper summarizes the recent studies of TNKS and its related inhibitors.
